AMPH - Company ID 0001297184
The table below shows Amphastar Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $719.89M | $731.97M | $644.39M | $498.99M | $437.77M | $349.85M |
| Cost of revenue | $363.83M | $358.11M | $293.27M | $250.13M | $238.03M | $206.51M |
| Gross profit | $356.06M | $373.86M | $351.12M | $248.86M | $199.74M | $143.34M |
| R&D | $85.84M | $73.91M | $73.74M | $74.77M | $60.93M | $67.23M |
Amphastar Pharmaceuticals, Inc. reported annual revenue of $719.89M for fiscal year 2025. That is down 1.7% from $731.97M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $255.16M (FY 2016) to $719.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $85.92M |
| $56.72M |
| $51.54M |
| $45.06M |
| $51.43M |
| $50.38M |
| Operating income | $140.40M | $205.42M | $196.99M | $107.50M | $69.89M | $10.95M |
| Income tax | $25.53M | $29.67M | $31.83M | $23.48M | $20.63M | $3.54M |
| Net income | $98.09M | $159.52M | $137.54M | $91.39M | $62.12M | $1.40M |
| EPS (diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 |